Iveric Bio gains after holder vote on Astellas takeover set for July 6
JHVEPhoto/iStock Editorial via Getty Images
Iveric Bio (NASDAQ:ISEE) rose 2% after the shareholder vote for its planned sale to Astellas Pharmaceuticals (OTCPK:ALPMY) was set for July 6. 
The July 6 date was disclosed in a proxy filing earlier on Monday.
The July date is an important one because it comes well before an Aug. 19 PDUFA date for Iveric's lead drug, Zimura. Some investors feared that the deal could run past the PDUFA date. 
Astellas Pharma (OTCPK:ALPMY) agreed to acquire Iveric Bio (ISEE) for $5.9 billion, or $40 a share, to add ophthalmology capabilities to the Japanese pharmaceutical giant.
Endpoints News reported last month that Bayer (OTCPK:BAYZF) and Amgen (AMGN) were interested in Iveric Bio (ISEE) before it agreed to the Astellas deal.
More on Iveric Bio, Astellas

Iveric bio, Still A 5+% Opportunity
Iveric Bio: ACP Advances As GATHER Results Continue To Impress